Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...2425262728293031323334...5960»
  • ||||||||||  Journal:  Pituitary disease: An update. (Pubmed Central) -  Nov 29, 2021   
    Acromegaly and Cushing's disease are rare but important diagnoses to detect. Pituitary disease is optimally managed in a specialist centre in the context of an established multidisciplinary team.
  • ||||||||||  Journal:  Prevalence and outcome of comorbidities associated with acromegaly. (Pubmed Central) -  Nov 29, 2021   
    Pituitary disease is optimally managed in a specialist centre in the context of an established multidisciplinary team. Treating acromegaly may relieve threatening associated morbidities such as aHT and DM2; nevertheless, only few comorbidities are reversible, which highlights the importance of treating acromegaly as early as possible.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  I-Con Study: Strict IGF-1 Control in Acromegaly (clinicaltrials.gov) -  Nov 22, 2021   
    P3,  N=10, Completed, 
    No abstract available. Active, not recruiting --> Completed | N=35 --> 10
  • ||||||||||  Journal:  Acromegaly accompanied by diabetes mellitus and polycystic kidney disease. (Pubmed Central) -  Nov 21, 2021   
    The patient's clinical course suggested common aspects of excessive GH secretion as an accelerating factor of the progression of diabetic nephropathy and PKD via direct and indirect pathways. Although coexisting acromegaly and PKD is clinically rare, vigilance for early diagnosis of acromegaly is appropriate in patients with diabetes and/or PKD, especially in those showing unexpected exacerbation of renal dysfunction.
  • ||||||||||  Journal:  Undiagnosed acromegaly as an underlying cause of sudden death. (Pubmed Central) -  Nov 10, 2021   
    The cause of death was heart failure due to end-stage acromegalic cardiopathy. Because the disease is slowly progressive, the individual himself, and the people close to him, might not have considered the acromegaly-related facial changes as abnormal.
  • ||||||||||  octreotide subcutaneous depot (CAM2029) / Camurus
    Trial completion date, Trial primary completion date:  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Nov 9, 2021   
    P3,  N=78, Recruiting, 
    Trial completion date: Apr 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Feb 2023 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  Clinical, Journal:  Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors. (Pubmed Central) -  Nov 7, 2021   
    The correlation of clinical findings and histological classification of pituitary adenomas is very important since every discrepancy has to be discussed between clinicians and pathologists. Based on data of the German Registry of Pituitary Tumors a table for examinations of correlations is shown in this review.
  • ||||||||||  Clinical, Journal:  Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea. (Pubmed Central) -  Nov 7, 2021   
    The annual incidence rate of Korean patients with acromegaly was similar to that reported in previous studies. Using nationwide population data, our study emphasized the importance of treatment in acromegaly patients.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  The effect of somatostatin analogs and acromegaly on the upper gastrointestinal system. (Pubmed Central) -  Nov 6, 2021   
    Using nationwide population data, our study emphasized the importance of treatment in acromegaly patients. The study showed that octreotide LAR treatment could be a risk factor in addition to known factors for the development of gastritis in patients with acromegaly.
  • ||||||||||  Retrospective data, Review, Journal:  HOMA-IR in acromegaly: a systematic review and meta-analysis. (Pubmed Central) -  Nov 6, 2021   
    This finding, confirms that insulin resistance is an early event in ACRO. Our results also suggest that HOMA-IR is not an adequate tool for assessing insulin resistance in those patients treated with SSAs.
  • ||||||||||  Clinical, Journal:  Outcome Squares integrating efficacy and safety, as applied to functioning pituitary adenoma surgery. (Pubmed Central) -  Nov 6, 2021   
    These results, together with the review of the literature, shed a new light on the role of GPR101 and SOX3 in pituitary function. Quality of a surgical intervention can be presented in 4 simple categories, integrating both efficacy and safety with flexibility to adapt to the individualized situation at patient, disease, and surgical strategy and to the outcome of interest.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  A Pituitary Society update to acromegaly management guidelines. (Pubmed Central) -  Nov 4, 2021   
    Given significant novel recent advances in understanding acromegaly natural history and individualized therapies, the Pituitary Society invited acromegaly experts to critically review the current literature in the context of Endocrine Society guidelines and Acromegaly Consensus Group statements. This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium.
  • ||||||||||  Clinical, Journal:  Predictors for remission after transsphenoidal surgery in acromegaly: a Dutch multicenter study. (Pubmed Central) -  Nov 4, 2021   
    This update focuses on how recent key advances affect treatment decision-making and outcomes, and also highlights the likely role of recently FDA-approved therapies as well as novel combination therapies within the treatment armamentarium. Maximum tumor diameter and random GH concentration at diagnosis are the best predictors for remission after TSS in acromegaly.
  • ||||||||||  cabergoline / Generic mfg., prednisone / Generic mfg.
    [VIRTUAL] Polyarthralgia in an Adult with Acromegaly: A Case Report () -  Nov 1, 2021 - Abstract #AAPMR2021AAPMR_412;    
    This case underscores the importance of recognizing polyarthralgia and DJD in patients with acromegaly, as radiographic findings in these patients are often uncharacteristic of traditional DJD. The focus of treatment should be on optimizing hormone levels and is otherwise similar to the approach for other degenerative musculoskeletal conditions.
  • ||||||||||  Preclinical, Journal, Gene Signature:  Differential gene signature in adipose tissue depots of growth hormone transgenic mice. (Pubmed Central) -  Oct 31, 2021   
    The miRNA prediction also suggested a modulation of T-cell-related biological process in Subq. In summary, the present study provides a unique resource for understanding the specific differences in gene expression that are driven by both excess GH action and AT depot location.
  • ||||||||||  Journal:  Facing Acromegaly During Rhinoplasty Procedure. (Pubmed Central) -  Oct 31, 2021   
    The authors report the case of a patient operated twice of a rhinoplasty before and after the acromegaly diagnosis for a very excessive nose. They emphasize the technical difficulties to efficiently reduce all the nasal dimensions, the importance of the soft tissues quality, as they cover the nasal cartilaginous framework, and the absolute necessity of biological normalization to provide a stable and satisfactory result.